Edgewise Therapeutics, Inc.
EWTX
Positions held
Your positionsEWTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Edgewise Therapeutics operates in the biotechnology sector, which is known for its potential high returns due to innovation and unmet medical needs.
- The company's market cap stands at approximately $4.35 billion, indicating a significant valuation in the biotech space.
- Despite current challenges, analysts have a 'buy' recommendation with a target mean price of $52.62.
- Edgewise Therapeutics has reported no revenue for multiple quarters, reflecting a lack of product commercialization.
- The company has incurred a net income loss of $57.33 million in Q2 2026, continuing a trend of negative earnings over the past several quarters.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $4.26B | Enterprise value | $3.80B | Trailing P/E | — | Forward P/E | -21.60 |
| PEG | — | Price / book | 9.44 | Beta | 0.36 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -38.0% | ROA | -25.0% | Debt / equity | 0.01 |
| Current ratio | 16.24 | Free cash flow | -$92.31M | Analyst recommendation | buy | Mean target | $52.62 |
| 52w high | $48.51 | 52w low | $14.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$57.3M | -$49.0M | -$50.2M | -$40.7M | -$36.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$61.9M | -$54.1M | -$56.0M | -$46.9M | -$42.6M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$168M | -$134M | -$100M | -$67.6M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$191M | -$159M | -$114M | -$71.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug
2026-10-08 · Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
2026-10-03 · Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
2026-10-02 · Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
2026-10-01 · Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2026-09-25 · Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
2026-09-23 · Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
2026-09-18 · Biotech Options Buzz: UTHR, NMRA, EWTX
2026-09-04 · Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
2026-09-02 · Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
2026-09-02 · Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Price (daily)
Full chart · RSI · MACD · patterns